相似文献
1
Teicoplanin: an alternative drug for the treatment of COVID-19?替考拉宁：治疗 COVID-19 的一种替代药物？
Int J Antimicrob Agents. 2020 Apr;55(4):105944. doi: 10.1016/j.ijantimicag.2020.105944. Epub 2020 Mar 13.
2
In Vitro Data of Current Therapies for SARS-CoV-2.针对 SARS-CoV-2 的当前疗法的体外数据。
Curr Med Chem. 2020;27(27):4542-4548. doi: 10.2174/0929867327666200513075430.
3
A global treatments for coronaviruses including COVID-19.全球针对冠状病毒（包括 COVID-19）的治疗方法。
J Cell Physiol. 2020 Dec;235(12):9133-9142. doi: 10.1002/jcp.29785. Epub 2020 May 11.
4
Drug repositioning is an alternative for the treatment of coronavirus COVID-19.药物重定位是治疗冠状病毒 COVID-19 的一种替代方法。
Int J Antimicrob Agents. 2020 Jun;55(6):105969. doi: 10.1016/j.ijantimicag.2020.105969. Epub 2020 Apr 9.
5
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.抗 SARS-CoV-2 再利用抗病毒药物的临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.
6
Perspectives for repurposing drugs for the coronavirus disease 2019.用于 2019 年冠状病毒疾病的药物再利用视角。
Indian J Med Res. 2020;151(2 & 3):160-171. doi: 10.4103/ijmr.IJMR_585_20.
7
Antiviral therapy for coronavirus disease 2019.2019冠状病毒病的抗病毒治疗
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 May 28;45(5):598-602. doi: 10.11817/j.issn.1672-7347.2020.200211.
8
COVID-19 Drug Discovery Using Intensive Approaches.利用强化方法进行 COVID-19 药物研发。
Int J Mol Sci. 2020 Apr 18;21(8):2839. doi: 10.3390/ijms21082839.
9
[Potential antiviral therapeutics for 2019 Novel Coronavirus].[2019新型冠状病毒的潜在抗病毒治疗方法]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):170-172. doi: 10.3760/cma.j.issn.1001-0939.2020.03.004.
10
Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.广谱抗病毒药物氯硝柳胺及其治疗潜力。
ACS Infect Dis. 2020 May 8;6(5):909-915. doi: 10.1021/acsinfecdis.0c00052. Epub 2020 Mar 10.
引用本文的文献
1
Autophagy and Respiratory Viruses: Mechanisms, Viral Exploitation, and Therapeutic Insights.自噬与呼吸道病毒：机制、病毒利用及治疗见解
Cells. 2025 Mar 12;14(6):418. doi: 10.3390/cells14060418.
2
Repositioning of Antibiotics in the Treatment of Viral Infections.抗生素在病毒感染治疗中的再定位。
Curr Microbiol. 2024 Oct 26;81(12):427. doi: 10.1007/s00284-024-03948-7.
3
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.COVID-19治疗潜在药物和疫苗的临床前与临床研究：近期更新的综合综述
Clin Pathol. 2024 Jul 26;17:2632010X241263054. doi: 10.1177/2632010X241263054. eCollection 2024 Jan-Dec.
4
The impact of the COVID-19 pandemic on spine care providers and patients.2019年冠状病毒病大流行对脊柱护理提供者和患者的影响。
N Am Spine Soc J. 2020 Apr 29;1:100003. doi: 10.1016/j.xnsj.2020.100003. eCollection 2020 May.
5
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
6
Age and Sex-Related Differences in Teicoplanine Isoform Concentrations in SARS-CoV-2 Patients.新冠病毒患者中替考拉宁异构体浓度的年龄和性别差异
Life (Basel). 2023 Aug 22;13(9):1792. doi: 10.3390/life13091792.
7
Possible therapeutic targets for SARS-CoV-2 infection and COVID-19.新型冠状病毒（SARS-CoV-2）感染及新冠肺炎（COVID-19）可能的治疗靶点。
J Allergy Infect Dis. 2021;2(3):75-83. doi: 10.46439/allergy.2.028.
8
Potential Drugs in COVID-19 Management.新冠病毒管理中的潜在药物。
Curr Med Chem. 2024;31(22):3245-3264. doi: 10.2174/0929867331666230717154101.
9
Towards the sustainable discovery and development of new antibiotics.迈向新型抗生素的可持续发现与开发。
Nat Rev Chem. 2021 Oct;5(10):726-749. doi: 10.1038/s41570-021-00313-1. Epub 2021 Aug 19.
10
Outpatient medications associated with protection from COVID-19 hospitalization.与预防 COVID-19 住院相关的门诊药物。
PLoS One. 2023 Mar 31;18(3):e0282961. doi: 10.1371/journal.pone.0282961. eCollection 2023.
本文引用的文献
1
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?氯喹抗冠状病毒的抗病毒作用的新见解：对 COVID-19 有何期待？
Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.
2
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
3
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）和 2019 年冠状病毒病（COVID-19）：疫情和挑战。
Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17.
4
Chloroquine for the 2019 novel coronavirus SARS-CoV-2.氯喹用于2019新型冠状病毒SARS-CoV-2。
Int J Antimicrob Agents. 2020 Mar;55(3):105923. doi: 10.1016/j.ijantimicag.2020.105923. Epub 2020 Feb 15.
5
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
6
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
7
Fighting viruses with antibiotics: an overlooked path.用抗生素对抗病毒：一条被忽视的途径。
Int J Antimicrob Agents. 2016 Oct;48(4):349-52. doi: 10.1016/j.ijantimicag.2016.07.004. Epub 2016 Aug 5.
8
Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).糖肽类抗生素可有效抑制晚期内体/溶酶体中的组织蛋白酶L，并阻断埃博拉病毒、中东呼吸综合征冠状病毒（MERS-CoV）和严重急性呼吸综合征冠状病毒（SARS-CoV）的进入。
J Biol Chem. 2016 Apr 22;291(17):9218-32. doi: 10.1074/jbc.M116.716100. Epub 2016 Mar 7.
Zotero 插件